Companies Enliven Therapeutics, Inc.
Enliven Therapeutics (ELVN): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me Enliven Therapeutics, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $11,918,926FY2025
CEO total pay was $11,918,926 in fiscal 2025; the brief holds no earlier figure for this CEO.
FY2025: salary $38,077 · bonus $0 · stock awards $0 · option awards $11,880,138
Order ELVN
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Richard Fair | $38,077 | $0 | $0 | $11,880,138 | $0 | $0 | $711 | $11,918,926 |
| President and Chief Executive Officer | ||||||||
| Sam Kintz | 624,154 | 0 | 0 | 7,952,553 | 316,800 | 0 | 15,140 | 8,908,647 |
| Former President and Chief Executive Officer | ||||||||
| Helen Collins | 523,000 | 0 | 0 | 2,775,279 | 188,280 | 0 | 15,140 | 3,501,699 |
| Chief Medical Officer | ||||||||
| Ben Hohl | 480,000 | 0 | 0 | 2,775,279 | 172,800 | 0 | 15,094 | 3,443,173 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Richard Fair | $11,918,926 | — | — | — |
| Sam Kintz | 8,908,647 | 5,461,660 | 8,279,751 | ↑ +3,446,987 |
| Helen Collins | 3,501,699 | 2,771,410 | 4,064,839 | ↑ +730,289 |
| Ben Hohl | 3,443,173 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company provides cash incentive compensation to its named executive officers based on their meeting of one or more corporate performance objectives, with the board selecting challenging goals that are achievable only by strong performance. The compensation committee reviews CEO recommendations and market data to determine total compensation, focusing on company results, individual contribution, and goal achievement.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Helen Collins | Option | 60,084 | 22.75 | — |
| Ben Hohl | Option | 60,084 | 22.75 | — |
| Helen Collins | Option | 100,209 | 14.85 | — |
| Ben Hohl | Option | 100,209 | 14.85 | — |
| Helen Collins | Option | 171,000 | 22.47 | — |
| Ben Hohl | Option | 171,000 | 22.47 | — |
| Richard Fair | Option | 875,000 | 18.77 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Richard Heyman, Ph.DIndependent · Board Chair · Compensation · Not standing for re-election | $46,000 | — | $365,000 | — | — | $411,000 |
| Jake Bauer, M.B.AIndependent · Audit (Chair) · Compensation | 61,000 | — | 324,985 | — | — | 385,985 |
| Andrew PhillipsIndependent | 57,500 | — | 324,985 | — | — | 382,485 |
| Mika Derynck, M.DIndependent · Audit · Nominating and Corporate Governance | 52,500 | — | 324,985 | — | — | 377,485 |
| Rishi Gupta, J.DIndependent · Audit · Compensation (Chair) | 52,000 | — | 324,985 | — | — | 376,985 |
| Rahul Ballal, Ph.DIndependent | 40,000 | — | 324,985 | — | — | 364,985 |
| Lori Kunkel, M.DIndependent · Nominating and Corporate Governance | 45,000 | — | 243,735 | — | — | 288,735 |
| Richard Fair, M.B.AEmployee director | — | — | — | — | — | 0 |
| Scott Garland, M.B.AIndependent · Nominating and Corporate Governance (Chair) · Newly elected | — | — | — | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $325,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $354,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $354,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Enliven Therapeutics as a peer
Companies that benchmark against ELVN
1 company names ELVN as a compensation peer
- Edgewise Therapeutics, Inc.EWTXFY2025
Each company listed discloses ELVN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ELVN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Enliven Therapeutics, Inc. | 2025 | Richard Fair | $38,077 | $0 | $11,880,138 | $0 | $11,918,926 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | 47,572,153 | 3,093,447 | 21,027 | 93.89% | Passed |
| 2025 | 2025-06-24 | — | — | — | — | — |
| 2024 | 2024-06-18 | — | — | — | — | — |
| 2023 | 2023-06-23 | — | — | — | — | — |
| 2022 | 2022-06-02 | — | — | — | — | — |
| 2021 | 2021-06-29 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-09 | 93.89%a |
| 2025 | 2025-06-24 | —b |
| 2024 | 2024-06-18 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (19 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Richard Fair. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 11,918,926. View filing ↗
- Section 01, Sam Kintz. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 8,908,647. View filing ↗
- Section 01, Helen Collins. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 3,501,699. View filing ↗
- Section 01, Ben Hohl. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 3,443,173. View filing ↗
- Section 08, Richard Heyman, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 411,000. View filing ↗
- Section 08, Jake Bauer, M.B.A. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 385,985. View filing ↗
- Section 08, Andrew Phillips. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 382,485. View filing ↗
- Section 08, Mika Derynck, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 377,485. View filing ↗
- Section 08, Rishi Gupta, J.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 376,985. View filing ↗
- Section 08, Rahul Ballal, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 364,985. View filing ↗
- Section 08, Lori Kunkel, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 288,735. View filing ↗
- Section 08, Richard Fair, M.B.A. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Scott Garland, M.B.A. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: —. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-10. Item 5.07 · say-on-pay result. As reported: 93.89% (votes for as printed: 47,572,153). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-25. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-18. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 354,000 + equity 0 + all other 0 = 354,000, summed across the director compensation table rows.
- Enliven Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Enliven Therapeutics, Inc.'s own proxy. As printed: 11,918,926. View filing ↗